BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 21823195)

  • 1. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
    Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.
    Lin CF; Shen LJ; Wu FL; Bai CH; Gau CS
    Br J Clin Pharmacol; 2012 Nov; 74(5):824-34. PubMed ID: 22364155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
    Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
    J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
    Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
    Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.
    Bhurke SM; Martin BC; Li C; Franks AM; Bursac Z; Said Q
    Pharmacotherapy; 2012 Sep; 32(9):809-18. PubMed ID: 22744772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
    Ho PM; Maddox TM; Wang L; Fihn SD; Jesse RL; Peterson ED; Rumsfeld JS
    JAMA; 2009 Mar; 301(9):937-44. PubMed ID: 19258584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.
    Ortolani P; Marino M; Marzocchi A; De Palma R; Branzi A
    J Cardiovasc Med (Hagerstown); 2012 Dec; 13(12):783-9. PubMed ID: 21252697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
    Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
    Vaduganathan M; Cannon CP; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Bhatt DL;
    Am J Med; 2016 Sep; 129(9):1002-5. PubMed ID: 27143321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.
    Ray WA; Murray KT; Griffin MR; Chung CP; Smalley WE; Hall K; Daugherty JR; Kaltenbach LA; Stein CM
    Ann Intern Med; 2010 Mar; 152(6):337-45. PubMed ID: 20231564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dilemma between gastroprotection and cardiovascular prevention].
    Venerito M; Kandulski A; Malfertheiner P
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2193-8. PubMed ID: 20979006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
    Tran M; Tafreshi J; Pai RG
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel and proton pump inhibitors--where do we stand in 2012?
    Drepper MD; Spahr L; Frossard JL
    World J Gastroenterol; 2012 May; 18(18):2161-71. PubMed ID: 22611308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
    O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
    Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
    J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
    Dunn SP; Steinhubl SR; Bauer D; Charnigo RJ; Berger PB; Topol EJ
    J Am Heart Assoc; 2013 Jan; 2(1):e004564. PubMed ID: 23525436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.